Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
Status:
Recruiting
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well acalabrutinib works in treating patients with chronic
graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host
disease caused by a stem cell transplant.